Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study

Abstract

This first prospective study provides objective data showing that early disclosure of MS diagnosis improves both the patient's QoL and psychological well-being. In addition, the results seem to suggest that CIS disclosure does not lead to the same favourable effects.

Mood and coping in clinically isolated syndrome and multiple sclerosis

“…This result is in accordance with a recent study in which the authors demonstrated that 30 days after diagnosis disclosure, both anxiety and depression were significantly rated as better compared to the start screening, and this improvement remained stable over the two annual follow-ups (23). This result is in accordance with a recent study in which the authors demonstrated that 30 days after diagnosis disclosure, both anxiety and depression were significantly rated as better compared to the start screening, and this improvement remained stable over the two annual follow-ups (23).…”

Most Scottish neurologists do not apply the 2010 McDonald criteria when diagnosing multiple sclerosis

“…There may also be other benefits; one study indicated that a diagnosis of MS rather than a CIS epsiode reduces anxiety and increases quality of life and 'psychological wellbeing' of patients. 11 Neurologists may be better suited to the uncertainty of a CIS than patients, who may find understanding MS easier for themselves, family and colleagues. However, what evidence there is suggests that if all patients were treated at this point, some would receive long term unnecessary treatment with potential adverse effects which has both medical and financial implications.…”

Fostering adherence to injectable disease-modifying therapies in multiple sclerosis

“…Patients should be educated about the nature of their disease, particularly concerning the variable and unpredictable course of MS, what treatments are likely to achieve and potential adverse events they might experience [16]. Interestingly, early disclosure of an MS diagnosis has been shown to improve patients' quality of life and psychological wellbeing [64].…”

“…The best approach to screening for depression in MS is to use the BDI with a cutoff score of 13 [62]. The Hamilton Rating Scale for Depression has been used in the Cognitive Impairment in Multiple Sclerosis study and the Chicago Multiscale Depression Inventory has been used in the Gruppo EmilianoRomagnolo Neurologi in Multiple Sclerosis study [63,64]. These scales can be used to measure the severity of depression and evolution of these symptoms in response to therapy, and also to differentiate between major depression and other depressive spectrum disorders which are common in patients with MS (e.g.…”